Camprosys 333mg Tablet 10s

Camprosys 333mg Tablet 10s contains acamprosate and is used to help maintain abstinence in individuals recovering from alcohol dependence. Alcohol dependence affects brain chemicals that regulate mood, cravings, and behaviour. Even after stopping alcohol, chemical imbalances in the brain may persist, leading to strong urges to drink again.

Acamprosate works by stabilising the chemical balance in the brain that has been disrupted by long-term alcohol use. Camprosys 333mg Tablet 10s is typically started after alcohol detoxification and is used alongside counselling, behavioural therapy, and social support programmes to reduce the risk of relapse.

Camprosys 333mg Tablet 10s contains acamprosate, a medication specifically designed to support individuals who have stopped drinking alcohol and wish to remain abstinent. Chronic alcohol use alters the balance between excitatory and inhibitory neurotransmitters in the brain, particularly glutamate and GABA systems. After alcohol cessation, this imbalance can cause withdrawal symptoms, anxiety, restlessness, and persistent cravings.

Acamprosate helps restore this disrupted neurochemical balance. It modulates glutamatergic neurotransmission by acting on NMDA receptors and enhancing inhibitory GABA activity indirectly. This stabilising effect reduces the physical and emotional discomfort that can trigger relapse.

Unlike some other medications for alcohol dependence, acamprosate does not cause sedation, does not produce euphoria, and is not habit-forming. It works best when initiated after the patient has achieved abstinence and is committed to a structured alcohol recovery programme.

The medicine does not treat acute alcohol withdrawal symptoms and should not be used for detoxification. Its effectiveness depends on consistent daily use and concurrent psychosocial support. Acamprosate is primarily eliminated through the kidneys and does not undergo significant liver metabolism, making it suitable for patients with liver impairment but requiring caution in those with kidney disease.

When taken as prescribed, Camprosys 333mg Tablet 10s significantly improves the likelihood of maintaining long-term sobriety and supports recovery from alcohol dependence.

Alcohol Dependence

Maintenance of abstinence in individuals who have stopped drinking.

Relapse Prevention

Reduces the risk of returning to alcohol use after detoxification.

Adjunct to Counselling

Used alongside behavioural therapy and support programmes to enhance recovery outcomes.

Supports Long-Term Abstinence

Helps reduce cravings and maintain sobriety.

Non-Addictive

Does not cause dependence or withdrawal symptoms.

Brain Chemical Stabilisation

Restores balance between excitatory and inhibitory neurotransmitters.

Liver-Friendly Option

Primarily eliminated via kidneys, suitable in patients with liver impairment.

Improves Recovery Outcomes

Works effectively when combined with counselling and social support.

Well-Tolerated

Generally causes mild and manageable side effects.

When taken as directed, Camprosys 333mg Tablet 10s is generally well-tolerated. Side effects are usually mild and may lessen over time.

Common Side Effects:

• Diarrhoea

• Nausea

• Abdominal pain

• Loss of appetite

• Headache

• Insomnia

Uncommon Side Effects:

• Anxiety

• Dizziness

• Skin rash

• Fatigue

Serious Side Effects (Require Immediate Medical Attention):

• Severe allergic reactions (rash, swelling of face or throat, difficulty breathing)

• Severe depression or suicidal thoughts

• Persistent severe diarrhoea leading to dehydration

Camprosys 333mg Tablet 10s should be taken exactly as prescribed by your doctor. The usual adult dose is two 333mg tablets taken three times daily (morning, afternoon, and evening), although dosing may vary depending on body weight and kidney function.

Tablets should be swallowed whole with water and can be taken with or without food. Consistency is important—take the medicine at evenly spaced intervals each day to maintain steady levels in the body.

Do not stop the medicine abruptly without consulting your doctor.

• Start treatment after achieving alcohol abstinence.

• Take doses consistently at evenly spaced times each day.

• Combine medication with counselling or support programmes.

• Stay hydrated, especially if diarrhoea occurs.

• Report mood changes or depressive symptoms immediately.

• Do not stop medication without medical advice.

• Attend regular follow-ups to assess progress.

• Inform your doctor about kidney problems before starting treatment.

• Alcohol (High): Reduces effectiveness and increases relapse risk.

• High-Fat Meals (Low): May slightly delay absorption but not clinically significant.

• Caffeine (Moderate): Excess intake may worsen anxiety or insomnia during recovery.

• Antidepressants (Low–Moderate): Generally safe; monitoring recommended.

• Benzodiazepines (Moderate): May increase sedation when used during detox.

• Opioids (Low): No significant pharmacological interaction but clinical supervision required.

• Disulfiram or Naltrexone (Moderate): May be used together under specialist supervision.

• Severe Kidney Disease (High): Contraindicated due to renal elimination.

• Depression or Suicidal Ideation (Moderate): Monitor closely for mood changes.

• Electrolyte Imbalance (Moderate): Severe diarrhoea may worsen imbalance.

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed one and continue with your regular dosing schedule.

Do not take a double dose to make up for the missed tablet. Missing doses may reduce the effectiveness of relapse prevention.